Market Closed -
Nasdaq
04:00:00 2024-05-24 pm EDT
|
5-day change
|
1st Jan Change
|
11.39
USD
|
-3.88%
|
|
+2.52%
|
-18.53%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
479.7
|
490.3
|
1,688
|
1,358
|
1,807
|
1,491
|
-
|
-
|
Enterprise Value (EV)
1 |
479.7
|
490.3
|
1,506
|
1,410
|
1,317
|
935
|
808.2
|
645.8
|
P/E ratio
|
-2.65
x
|
-5.71
x
|
24.7
x
|
5.4
x
|
-280
x
|
71.2
x
|
31.6
x
|
24.2
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
13.6
x
|
10.5
x
|
3.84
x
|
1.88
x
|
7.78
x
|
5.23
x
|
4.26
x
|
3.65
x
|
EV / Revenue
|
13.6
x
|
10.5
x
|
3.43
x
|
1.95
x
|
5.67
x
|
3.28
x
|
2.31
x
|
1.58
x
|
EV / EBITDA
|
-
|
-
|
10.6
x
|
4.86
x
|
-44.3
x
|
112
x
|
12.9
x
|
6.55
x
|
EV / FCF
|
-3.31
x
|
-5.11
x
|
4.62
x
|
25.4
x
|
13.7
x
|
467
x
|
14.7
x
|
7.18
x
|
FCF Yield
|
-30.2%
|
-19.6%
|
21.6%
|
3.94%
|
7.32%
|
0.21%
|
6.8%
|
13.9%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
83,865
|
110,173
|
119,952
|
127,585
|
129,261
|
130,892
|
-
|
-
|
Reference price
2 |
5.720
|
4.450
|
14.07
|
10.64
|
13.98
|
11.39
|
11.39
|
11.39
|
Announcement Date
|
3/11/20
|
2/25/21
|
2/28/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
35.22
|
46.55
|
439.4
|
722.7
|
232.3
|
284.9
|
350.2
|
408
|
EBITDA
1 |
-
|
-
|
141.5
|
290.2
|
-29.75
|
8.355
|
62.48
|
98.64
|
EBIT
1 |
-134.8
|
-68.37
|
134.5
|
283.5
|
-37.03
|
-14.23
|
20.45
|
54.67
|
Operating Margin
|
-382.87%
|
-146.87%
|
30.6%
|
39.23%
|
-15.94%
|
-4.99%
|
5.84%
|
13.4%
|
Earnings before Tax (EBT)
1 |
-152.6
|
-75.24
|
77.52
|
294.3
|
-4.367
|
18.66
|
54.03
|
92.74
|
Net income
1 |
-155.9
|
-75.24
|
76.71
|
293.2
|
-6.389
|
18.57
|
48.03
|
69.09
|
Net margin
|
-442.57%
|
-161.63%
|
17.46%
|
40.56%
|
-2.75%
|
6.52%
|
13.72%
|
16.93%
|
EPS
2 |
-2.160
|
-0.7800
|
0.5700
|
1.970
|
-0.0500
|
0.1600
|
0.3600
|
0.4700
|
Free Cash Flow
1 |
-145
|
-96.01
|
326.1
|
55.58
|
96.46
|
2
|
55
|
90
|
FCF margin
|
-411.79%
|
-206.25%
|
74.2%
|
7.69%
|
41.53%
|
0.7%
|
15.71%
|
22.06%
|
FCF Conversion (EBITDA)
|
-
|
-
|
230.43%
|
19.15%
|
-
|
23.94%
|
88.02%
|
91.24%
|
FCF Conversion (Net income)
|
-
|
-
|
425.03%
|
18.96%
|
-
|
10.77%
|
114.5%
|
130.27%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/11/20
|
2/25/21
|
2/28/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
195.1
|
114
|
256.5
|
167.7
|
184.5
|
46.92
|
60.25
|
69.51
|
55.6
|
50.79
|
76.59
|
87.43
|
70.03
|
76.04
|
90.9
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
80.72
|
30.76
|
128.2
|
61.4
|
63.14
|
-30.25
|
-3.405
|
5.116
|
-8.491
|
-17.77
|
3.872
|
11.38
|
-8.491
|
0.874
|
-
|
Operating Margin
|
41.38%
|
26.99%
|
50%
|
36.6%
|
34.22%
|
-64.46%
|
-5.65%
|
7.36%
|
-15.27%
|
-34.99%
|
5.06%
|
13.02%
|
-12.12%
|
1.15%
|
-
|
Earnings before Tax (EBT)
1 |
100.6
|
32.86
|
129.4
|
64.09
|
67.97
|
-23.72
|
4.207
|
14.15
|
0.996
|
-11.5
|
10.92
|
17
|
-3.241
|
-
|
-
|
Net income
1 |
99.78
|
32.86
|
128.8
|
63.81
|
67.73
|
-24.33
|
3.431
|
14.29
|
0.219
|
-8.721
|
10.92
|
17
|
-3.241
|
-
|
-
|
Net margin
|
51.15%
|
28.83%
|
50.2%
|
38.04%
|
36.71%
|
-51.85%
|
5.69%
|
20.56%
|
0.39%
|
-17.17%
|
14.26%
|
19.44%
|
-4.63%
|
-
|
-
|
EPS
2 |
0.5500
|
0.2200
|
0.8700
|
0.4300
|
0.4500
|
-0.1900
|
0.0300
|
0.1000
|
-
|
-0.0700
|
0.0625
|
0.1200
|
0.0125
|
0.0400
|
0.0800
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/28/22
|
5/5/22
|
8/4/22
|
11/3/22
|
2/23/23
|
5/2/23
|
8/3/23
|
11/2/23
|
2/22/24
|
5/8/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
52.4
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
181
|
-
|
490
|
556
|
683
|
845
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
0.1805
x
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-145
|
-96
|
326
|
55.6
|
96.5
|
2
|
55
|
90
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
22.4
|
4.07
|
9.48
|
7.14
|
4.1
|
3.75
|
4
|
4
|
Capex / Sales
|
63.6%
|
8.75%
|
2.16%
|
0.99%
|
1.77%
|
1.32%
|
1.14%
|
0.98%
|
Announcement Date
|
3/11/20
|
2/25/21
|
2/28/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Last Close Price
11.39
USD Average target price
25.91
USD Spread / Average Target +127.50% Consensus |
1st Jan change
|
Capi.
|
---|
| -18.53% | 1.49B | | +12.30% | 118B | | +12.15% | 106B | | -8.14% | 23.4B | | -1.69% | 21.78B | | -10.60% | 18.09B | | -41.25% | 16.72B | | -15.33% | 15.97B | | +5.80% | 14.03B | | +28.03% | 11.67B |
Bio Therapeutic Drugs
|